Patent intelligence · US
US 12161724
Compositions and methods related to tumor activated antibodies targeting EGFR and effector cell antigens
Compositions and methods related to tumor activated antibodies targeting EGFR and effector cell antigens
Patent details — US 12161724
- Jurisdiction
- US
- Status
- granted
- Grant date
- Dec 10, 2024
- Expiration
- Dec 5, 2044
- Applicant
- JANUX THERAPEUTICS, INC.
- Claims
- 21
- CPC classes
- A61K, A61K2039/505, A61K38/00, A61K47/6843
Quick answer
US 12161724 (Compositions and methods related to tumor activated antibodies targeting EGFR and effector cell antigens) is held by JANUX THERAPEUTICS, INC.. Status: granted. Granted Dec 10, 2024. Expires Dec 5, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- JANUX THERAPEUTICS, INC.
- Grant date
- Expiration
- Claims
- 21
- CPC classes
- A61K, A61K2039/505, A61K38/00, A61K47/6843, A61K47/6849, A61K47/6851
More from JANUX THERAPEUTICS, INC.
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 12161724?
US 12161724 (Compositions and methods related to tumor activated antibodies targeting EGFR and effector cell antigens) is held by JANUX THERAPEUTICS, INC.. Status: granted. Granted Dec 10, 2024. Expires Dec 5, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12161724?
JANUX THERAPEUTICS, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 2 pharmaceutical patents for this assignee.
When does US 12161724 expire?
Our index shows an expiration date of Dec 5, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.